Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain.
Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Sep;12(5):e1637. doi: 10.1002/wnan.1637. Epub 2020 Apr 29.
Nanomedicine and drug delivery technologies play a prominent role in modern medicine, facilitating better treatments than conventional drugs. Nanomedicine is being increasingly used to develop new methods of cancer diagnosis and treatment, since this technology can modulate the biodistribution and the target site accumulation of chemotherapeutic drugs, thereby reducing their toxicity. Regenerative medicine provides another area where innovative drug delivery technology is being studied for improved tissue regeneration. Drug delivery systems can protect therapeutic proteins and peptides against degradation in biological environments and deliver them in a controlled manner. Similarly, the combination of drug delivery systems and stem cells can improve their survival, differentiation, and engraftment. The present review summarizes the most important steps carried-out by the group of Prof Blanco-Prieto in nanomedicine and drug delivery technologies. Throughout her scientific career, she has contributed to the area of nanomedicine to improve anticancer therapy. In particular, nanoparticles loaded with edelfosine, doxorubicin, or methotrexate have demonstrated great anticancer activity in preclinical settings of lymphoma, glioma, and pediatric osteosarcoma. In regenerative medicine, a major focus has been the development of drug delivery systems for brain and cardiac repair. In this context, several microparticle-based technologies loaded with biologics have demonstrated efficacy in clinically relevant animal models such as monkeys and pigs. The latest research by this group has shown that drug delivery systems combined with cell therapy can achieve a more complete and potent regenerative response. Cutting-edge areas such as noninvasive intravenous delivery of cardioprotective nanomedicines or extracellular vesicle-based therapies are also being explored. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
纳米医学和药物输送技术在现代医学中发挥着重要作用，能够提供比传统药物更好的治疗效果。纳米医学正被越来越多地用于开发新的癌症诊断和治疗方法，因为这项技术可以调节化疗药物的生物分布和靶部位积累，从而降低其毒性。再生医学提供了另一个正在研究创新药物输送技术以促进组织再生的领域。药物输送系统可以保护治疗性蛋白质和肽免受生物环境中的降解，并以受控的方式输送它们。同样，药物输送系统和干细胞的结合可以提高它们的存活率、分化和植入。本文总结了 Blanco-Prieto 教授在纳米医学和药物输送技术方面所进行的最重要的步骤。在她的整个科学生涯中，她一直致力于纳米医学领域，以改善癌症治疗效果。特别是，载有埃德尔福辛、阿霉素或甲氨蝶呤的纳米颗粒在淋巴瘤、神经胶质瘤和小儿骨肉瘤的临床前研究中表现出了很强的抗癌活性。在再生医学中，药物输送系统的开发是一个主要关注点，用于脑和心脏修复。在这方面，几种载有生物制品的基于微粒的技术在猴子和猪等临床相关动物模型中证明了疗效。该小组的最新研究表明，药物输送系统与细胞治疗相结合可以实现更完全和有效的再生反应。该小组还在探索一些前沿领域，如心脏保护纳米药物的非侵入性静脉输送或基于细胞外囊泡的治疗方法。本文属于以下类别： 治疗方法和药物发现 > 新兴技术 治疗方法和药物发现 > 纳米医学治疗肿瘤疾病。
